Researchers find low-dose PET/CT best imaging method for lymphoma

Article

Low-dose PET/CT demonstrates the best sensitivity and specificity for initial staging of lymphoma, according to a study presented on Thursday at the RSNA meeting.

Low-dose PET/CT demonstrates the best sensitivity and specificity for initial staging of lymphoma, according to a study presented on Thursday at the RSNA meeting.

Dr. Immaculada Pinilla Fernandez, from the University Hospital La Paz in Madrid, Spain, and colleagues prospectively studied 108 consecutive patients with biopsy-proven non-Hodgkin's lymphoma as well as Hodgkin's lymphoma. The patients underwent initial staging with F-18 FDG-PET/CT that included a low-dose CT and a PET study followed by a full-dose, contrast-enhanced CT.

Low-dose PET/CT correctly classified lymphoma stage in 77.5% of patients, while PET correctly classified 65.6% and contrast-enhanced CT identified 63%. The researchers found the sensitivity and specificity of low-dose PET/CT to be 94.8% and 90.5%, respectively. The positive and negative predictive values were 93% and 92%. PET sensitivity and specificity was 90% and 86%. Sensitivity and specificity for CT was 88% and 90%.

Since low-dose PET/CT achieved the best sensitivity and specificity, radiation dose could be reduced and use of intravenous iodinated contrast material could be avoided in patients with lymphoma, Fernandez said.

Recent Videos
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.